Erin L Schenk
Overview
Explore the profile of Erin L Schenk including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
39
Citations
777
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Li H, Liu J, Lan S, Zhong R, Cui Y, Christopoulos P, et al.
Transl Lung Cancer Res
. 2024 Jan;
12(12):2538-2549.
PMID: 38205210
Background: Anaplastic lymphoma kinase () rearrangement is one of the most important drivers in non-small cell lung cancer (NSCLC). Despite the effectiveness to canonical 3'- fusions, the clinical efficacy of...
12.
13.
Schenk E
Transl Lung Cancer Res
. 2023 Mar;
12(2):322-336.
PMID: 36895933
Background And Objective: Patients with metastatic anaplastic lymphoma kinase (ALK)+ non-small cell lung cancer (NSCLC) often experience years of disease control on targeted therapies but the disease eventually develops resistance...
14.
Langston J, Patil T, Camidge D, Bunn P, Schenk E, Pacheco J, et al.
Lung Cancer
. 2023 Feb;
178:103-107.
PMID: 36809719
Introduction: For extensive brain metastases (BrM) presentations arising from oncogene-addicted lung cancer, tyrosine kinase inhibitors (TKIs) with high response rates in the central nervous system (CNS) could potentially downstage the...
15.
Kleczko E, Hinz T, Nguyen T, Gurule N, Navarro A, Le A, et al.
NPJ Precis Oncol
. 2023 Feb;
7(1):15.
PMID: 36739466
Lung cancers bearing oncogenic EML4-ALK fusions respond to targeted tyrosine kinase inhibitors (TKIs; e.g., alectinib), with variation in the degree of shrinkage and duration of treatment (DOT). However, factors that...
16.
Priest K, Le A, Gebregzabheir A, Nijmeh H, Reis G, Mandell M, et al.
NPJ Precis Oncol
. 2023 Jan;
7(1):9.
PMID: 36690705
Patients with metastatic NSCLC bearing a ROS1 gene fusion usually experience prolonged disease control with ROS1-targeting tyrosine kinase inhibitors (TKI), but significant clinical heterogeneity exists in part due to the...
17.
Schenk E, Boland J, Withers S, Bulur P, Dietz A
Cancers (Basel)
. 2022 Sep;
14(18).
PMID: 36139660
Patients with early-stage lung adenocarcinoma have a high risk of recurrent or metastatic disease despite undergoing curative intent therapy. We hypothesized that increased CD14+ cells within the tumor microenvironment (TME)...
18.
Seal S, Wrobel J, Johnson A, Nemenoff R, Schenk E, Bitler B, et al.
BMC Res Notes
. 2022 Jun;
15(1):215.
PMID: 35725622
Objective: Multiplex immunohistochemistry (mIHC) and multiplexed ion beam imaging (MIBI) images are usually phenotyped using a manual thresholding process. The thresholding is prone to biases, especially when examining multiple images...
19.
Vu T, Wrobel J, Bitler B, Schenk E, Jordan K, Ghosh D
PLoS Comput Biol
. 2022 Jun;
18(6):e1009486.
PMID: 35704658
The tumor microenvironment (TME), which characterizes the tumor and its surroundings, plays a critical role in understanding cancer development and progression. Recent advances in imaging techniques enable researchers to study...
20.
Hubbard J, Yin J, Schenk E, Qin R, Reid J, Strand C, et al.
Invest New Drugs
. 2021 Sep;
40(1):115-123.
PMID: 34515877
Purpose: Targeting the vascular endothelial growth factor (VEGF) pathway improves progression free survival in multiple advanced malignancies but durable responses are uncommon. Inhibition of the VEGF pathway at multiple levels...